Drug Profile
Palifosfamide - Alaunos Therapeutics
Alternative Names: IPM (ZIO-201); IPM-tris; Isophosphamide mustard-tris; Isophosphoramide mustard; Palifosfamide-tris; ZIO-201; ZIO-201-T; ZymafosLatest Information Update: 31 Jan 2022
Price :
$50
*
At a glance
- Originator Dekk-Tec
- Developer Alaunos Therapeutics; ZIOPHARM Oncology
- Class Antineoplastics; Cyclophosphamides; Oxazines; Small molecules
- Mechanism of Action Alkylating agents; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Haematological malignancies; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Testicular cancer
Most Recent Events
- 26 Jan 2022 ZIOPHARM Oncology is now called Alaunos Therapeutics
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in USA (IV)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV)